Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Inman, Brant
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Recruiting	3	190	Japan, US, RoW	Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	12/27	12/29
IGPC-5, NCT04053842: Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy	Recruiting	2	45	Canada	PET Scan, PSMA PET, [18F]PSMA-1007 Injection, PSMA, Sodium MRI, Multiparametric MRI, mpMRI	Glenn Bauman, Western University, Canada, United States Department of Defense, Centre for Probe Development and Commercialization	Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm	07/24	08/24
GUNS, NCT04812366: Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer	Recruiting	2	315	Canada, US	Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab	University of British Columbia, Janssen Inc., University Health Network, Toronto	Prostate Cancer	04/26	04/26
CAPTAIN, NCT05027477: A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer	Recruiting	N/A	201	Europe, Canada, US	Radical Prostatectomy, TULSA Procedure, TULSA-PRO	Profound Medical Inc.	Prostate Cancer, Prostate Adenocarcinoma	12/24	12/34
Shah, Paras
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Recruiting	3	190	Japan, US, RoW	Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	12/27	12/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
HEAT, NCT06014255: Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer	Recruiting	2	219	US	Enoblituzumab, MGA271, Standard of Care	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics	Prostate Cancer	03/29	03/29
Agarwal, Gautam
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Recruiting	3	190	Japan, US, RoW	Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	12/27	12/29